Research Gaps in Fragile X Syndrome: An Updated Literature Review to Inform Clinical and Public Health Practice

被引:2
作者
Raspa, Melissa [1 ,2 ]
Wheeler, Anne [1 ]
Okoniewski, Katherine C. [1 ]
Edwards, Anne [1 ]
Scott, Samantha [1 ]
机构
[1] RTI Int Genom Ethics & Translat Res Program, Res Triangle Pk, NC USA
[2] RTI Int Genom Ethics & Translat Res Program, POB 12194,3040 East Cornwallis Rd, Res Triangle Pk, NC 27709 USA
关键词
fragile X syndrome; clinical phenotype; public health needs; treatment; family needs; SCHOOL-AGED BOYS; QUALITY-OF-LIFE; LANGUAGE INTERVENTION; ADAPTIVE-BEHAVIOR; AUTISM SYMPTOMS; ADOLESCENT BOYS; ECONOMIC BURDEN; DOWN-SYNDROME; YOUNG-ADULTS; DOUBLE-BLIND;
D O I
10.1097/DBP.0000000000001134
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Objective:The phenotypic impact of fragile X syndrome (FXS) has been well-documented since the discovery of the fragile X messenger ribonucleoprotein 1 gene 30 years ago. However, gaps remain in clinical and public health research. The purpose of this literature review was to determine the extent to which these gaps have been addressed and identify targeted areas of future research.Methods:We conducted an electronic search of several scientific databases using a variety of key words. The search focused on 5 areas identified as research gaps by an earlier review: (1) diagnosis, (2) phenotypic presentation, (3) familial impact, (4) interventions and treatments, and (5) life span perspectives. Inclusion criteria included publication between 2014 and 2020, focus on human subjects, and publication in English. A total of 480 articles were identified, 365 were reviewed, and 112 are summarized in this review.Results:Results are organized into the following categories: (1) FXS phenotype and subtypes (FXS subtypes, medical profile, cognitive/developmental profile, social and behavioral profile); (2) needs of adults; (3) public health needs (clinical diagnosis and newborn screening, health care needs, and access); (4) treatment (treatment priorities, pharmacological treatments, and behavioral and educational interventions); and (5) families (economic burden and mother-child relationship).Conclusion:Despite the progress in many areas of FXS research, work remains to address gaps in clinical and public health knowledge. We pose 3 main areas of focused research, including early detection and diagnosis, determinants of health, and development and implementation of targeted interventions.
引用
收藏
页码:E56 / E65
页数:10
相关论文
共 120 条
  • [21] Coleman JM, 2014, LIFE SPAN DISABIL, V17, P59
  • [22] People with intellectual disability: What do we know about adulthood and life expectancy?
    Coppus, A. M. W.
    [J]. DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS, 2013, 18 (01) : 6 - 16
  • [23] Caregiver Preferences for the Treatment of Males with Fragile X Syndrome
    Cross, James
    Yang, Jui-Chen
    Johnson, F. Reed
    Quiroz, Jorge
    Dunn, Judith
    Raspa, Melissa
    Bailey, Donald B., Jr.
    [J]. JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2016, 37 (01) : 71 - 79
  • [24] Fragile X syndrome clinical trials: exploring parental decision-making
    D'Amanda, C. S.
    Peay, H. L.
    Wheeler, A. C.
    Turbitt, E.
    Biesecker, B. B.
    [J]. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2019, 63 (08) : 926 - 935
  • [25] Friendships and social participation as markers of quality of life of adolescents and adults with fragile X syndrome and autism
    DaWalt, Leann Smith
    Usher, Lauren V.
    Greenberg, Jan S.
    Mailick, Marsha R.
    [J]. AUTISM, 2019, 23 (02) : 383 - 393
  • [26] The Fragile X Protein and Genome Function
    Dockendorff, Thomas C.
    Labrador, Mariano
    [J]. MOLECULAR NEUROBIOLOGY, 2019, 56 (01) : 711 - 721
  • [27] Risperidone Treatment for Irritability in Fragile X Syndrome
    Dominick, Kelli C.
    Wink, Logan K.
    Pedapati, Ernest V.
    Shaffer, Rebecca
    Sweeney, John A.
    Erickson, Craig A.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2018, 28 (04) : 274 - 278
  • [28] Metformin as targeted treatment in fragile X syndrome
    Dy, A. B. C.
    Tassone, F.
    Eldeeb, M.
    Salcedo-Arellano, M. J.
    Tartaglia, N.
    Hagerman, R.
    [J]. CLINICAL GENETICS, 2018, 93 (02) : 216 - 222
  • [29] Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis
    Eckert, Eleanor M.
    Dominick, Kelli C.
    Pedapati, Ernest V.
    Wink, Logan K.
    Shaffer, Rebecca C.
    Andrews, Howard
    Choo, Tse-Hwei
    Chen, Chen
    Kaufmann, Walter E.
    Tartaglia, Nicole
    Berry-Kravis, Elizabeth M.
    Erickson, Craig A.
    [J]. JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2019, 49 (11) : 4595 - 4602
  • [30] Facilitating individuals and families affected by fragile X syndrome to participate in medication trials
    Eley, S. E. A.
    McKechanie, A. G.
    Campbell, S.
    Stanfield, A. C.
    [J]. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2020, 64 (11) : 864 - 874